Maria Themeli

Maria Themeli is Assistant Professor at the department of Hematology at the Amsterdam UMC. Her group focuses on the treatment of malignancies with cellular immunotherapy, in particular chimeric antigen receptor engineered T cells (CAR T cells). The ultimate purpose of this group is to develop safe, effective, and affordable CAR T cell therapies for hematological malignancies as well as solid tumors. Towards this goal her group applies novel strategies, such as: development of dual-targeting CAR T, optimizing co-stimulation, development of new CAR designs, and engineering induced pluripotent stem cells as a source of CAR T cells.